Tag Archive for: Roche

Now in Phase III with its small molecule orforglipron, Eli Lilly is leading the oral GLP-1 race against Novo Nordisk, Pfizer, Roche and others.

Last week, Swiss contract manufacturer Lonza announced it was paying $1.2 billion to buy a Roche manufacturing facility in Vacaville, California. The deal is meant to boost Lonza’s production of commercial mammalian products, which are made from cells isolated from animal tissues, and to expand its U.S. manufacturing footprint. The acquisition is indicative of the growing reliance of biopharma companies on contract manufacturers for biologics.

Despite meeting its primary endpoint in a late-stage generalized myasthenia gravis trial, Roche and Chugai Pharmaceutical’s Enspryng did not demonstrate clinical benefit as expected, the companies announced Thursday.

The site, designed to produce large-scale biologics for Roche’s Genentech, will help Lonza meet the demand for commercial mammalian products from other companies and make molecules in development

Bristol Myers Squibb secured another late-phase immuno-oncology victory Wednesday, showing that the combination of Opdivo and Yervoy improved overall survival in a patient population served by rival checkpoint inhibitors from AstraZeneca and Roche.

In a neurology update for investors, Roche touted data from a small Ib/IIa trial for trontinemab, an investigational therapy for Alzheimer’s disease which demonstrated “rapid and robust” amyloid plaque reduction.

The companies stated that their experimental drug against high blood pressure was shown to work when used in combination with the standard of care in a phase 2 trial.

Roche on Sunday released results from the first stage of the Phase III OUtMATCH study, demonstrating that its asthma drug Xolair (omalizumab) can significantly reduce severe allergic reactions in patients with several food allergies.

San Francisco-based Rigel Pharmaceuticals on Thursday announced it will acquire the U.S. rights to Blueprint Medicines’ FDA-approved non-small cell lung cancer drug Gavreto (pralsetinib).

Merger and acquisition activity is on the rise after the biopharma industry moved on from the COVID-19 pandemic, while the role of AI in drug development is reaching new levels.